Ruti Aga's six-year ban: the fake prescription that outweighed the banned substance

One line in the Athletics Integrity Unit's statement made me read it three times: the clinic that issued Ruti Aga's prescription had never existed. No pandemic closure, no relocation, no lost archive. There was simply never any such facility operating at the address printed on the form. The doctor who signed it was a family member with no medical registration number. Asked to explain, this person produced an old prescription pad, claiming to have kept it from a former workplace. That facility replied, briefly, that the person had never appeared on their staff list. And the clinic named on the form confirmed that the prescription did not come from them. Three layers of verification, three denials, in one file. A 32-year-old marathoner who won the 2026 Tokyo Marathon ended her career with a piece of paper rejected by three separate parties. I sat with that detail for a long time. A marathon is 42.195 kilometres, a little over two hours, decided by tens of thousands of footfalls and a handful of decisions at the 35th kilometre. This case was decided by a prescription pad. The scoreboard ends the match, but most of the story lies beneath it — and this time, what lay beneath was a sheet of paper. Ruti Aga, Ethiopian, 32, belongs to the elite tier of women's marathon running. She won Tokyo in 2026 and finished runner-up three times at World Marathon Majors events. The statement does not specify which three races those were. That is a notable data gap, because it means her form curve cannot be reconstructed from official sources alone; it has to rest on the professional memory of people who follow the roads. In March she won a half marathon in China. No time was disclosed. This is the largest technical blind spot in the whole file: we know the legal outcome but not the sporting one. The performance cannot be placed against her personal best, against a course record, or against the world level of that season. Any inference about what that race meant athletically is speculation. The sample returned methylprednisolone. Aga said it was treatment for a knee injury. She did not deny using the substance; she denied using it to enhance performance, and offered a medical explanation that is, in principle, verifiable. A word on the substance, because most of the reporting I read called it a steroid. Methylprednisolone is a synthetic glucocorticoid, class S9 under the World Anti-Doping Agency (WADA) list, prohibited in-competition only, and classified as a Specified Substance. It is not an anabolic steroid. The label is not a trivial matter of vocabulary: it inflates the perceived severity of the case above its actual nature, and it makes the public misunderstand the kind of error this athlete actually committed. Specified Substances exist for cases more plausibly tied to inadvertent or therapeutic use. The baseline sanction is therefore lower, and there is always a pathway to mitigation if the athlete can show no intent to enhance performance. For glucocorticoids, the baseline is two years. Therapeutic Use Exemption, TUE for short, is the door every professional knows about. With a valid TUE, treatment of an injury is not a violation. Route of administration matters enormously: an intra-articular injection close to competition triggers the in-competition prohibition absent an exemption. The statement does not disclose the route in Aga's case, and this is a detail I have to leave blank. The final outcome is a six-year ban, effective from 10 September. The year of the positive test and the year of the provisional suspension are not stated in the source. I record that plainly rather than filling the gap with a plausible-sounding guess. The structure of the sanction is where the analysis has to start: two years for the presence of a prohibited substance, plus four years for tampering, served consecutively rather than concurrently. The WADA Code permits accumulation in this way when a single file contains multiple violations, and that is how a case beginning with a therapeutic injection ends with six years away from the roads. What separates this file from hundreds of other adverse findings is the evidentiary chain on the fabrication, and the way it was verified. The AIU does not argue by impression. They called the clinic named on the form and asked whether the prescription was theirs. They checked the registration status of the signing doctor. They asked the former employer whether this person had ever worked there. Three questions, three denials, and the file closes. That verification practice deserves emphasis because it changes the nature of the game. Forged documents were once cheap tools with a reasonable success rate, because cross-checking required time and relationships that smaller bodies lacked. Not anymore. One phone call, one registry lookup, one confirmation email from a human-resources department — verification now takes days, not months. Anyone who believed an old prescription pad could cover a positive sample has misjudged the system they were up against. Read the structure closely and a paradox appears: the penalty for the cover-up is twice the penalty for the underlying act. Four years for fabricating documents, two years for the substance in the body. Under WADA's framework, tampering during results management is an independent violation with its own sanction range, and that range is heavier than the range for a Specified Substance. This athlete converted a two-year case with genuine mitigating potential into a six-year ban that cannot be argued with. Reconstruct the compliant path to see the distance. Had a glucocorticoid injection for a knee injury been administered under a valid TUE, or disclosed transparently with a retroactive exemption application, the outcome could have been no violation at all. Had the use been procedurally wrong but honestly declared, the outcome could have been a far lighter sanction, possibly a suspended one with much less publicity. The distance between those two scenarios is not an injection. It is a document. There is another layer that gets little attention: the economics of road racing. The March half marathon in China was almost certainly an appearance-fee race, in the regional tier where testing density is lower than at the majors, and it sits inside the well-worn current of East African athletes racing in Asia. That result will almost certainly be annulled, and the prize money forfeited. The consequence belongs to a road-racing economy, not purely to sport. From my experience covering the major marathons, appearance fees are the most stable and least publicised income stream for a distance runner at the middle and upper levels. They do not appear in results lists, they do not appear in sponsorship files, and they vanish the moment a suspension is signed. A runner can live for years on three to five invited races a season. A six-year ban does not erase one season; it erases the entire revenue line. Age 32 places the sanction at its cruellest coordinate. The elite peak window for women marathoners commonly extends past 35, occasionally to 37 for athletes with a good base and few injuries. Aga was inside that window, not past it. A ban effective from 10 September returns her to eligibility at roughly 38, after six years without a single official race. 214 days without competition taught me to listen for the pulse of persistence. But those 214 days were a silence with an end date, a target, someone waiting. Six years is a different kind of silence: no race waiting, no benchmark to hold onto, no week to count down. A marathoner can come back after 214 days. Coming back to major podium level after six years, at 38, is a hypothesis for which I cannot find a convincing precedent. Market value collapses before sporting value does. Invitations to major races disappear within the next season. Sponsorship contracts routinely include morality clauses allowing partners to exit when an athlete is found in breach of anti-doping rules, and this is a textbook case for triggering them. For an athlete whose income comes mainly from appearance fees and prize money, six years is a commercial sentence before it is a sporting one. The most instructive part of the file, to my reading, sits in the support layer around the athlete. A relative with no registration. An old prescription pad. A clinic address that does not exist. That is not a description of a sophisticated doping operation; it is a description of people with no compliance expertise trying to cover a medical error with the tools they had. The amateurism is itself a diagnosis of how thin the medical and legal scaffolding around the athlete was. In the East African road-running system, very few athletes have dedicated compliance counsel. They have a coach, an agent, a training-group doctor, but rarely someone whose job is to read the rules and answer procedural questions. When an adverse finding lands, the instinctive responses are human: explain, find paperwork, call someone you know. In the current system, those three instincts are three ways of lengthening your own ban. I once sat in a press area in Paris in 2026 and watched a 200m runner go down on the track with a torn hamstring at the very start of her drive phase, then answer questions in tears. I withdrew for two days afterwards and answered no messages. People remember the goals; I remember the exhausted legs after the whistle. The Aga case taught me something different: sometimes what tears is not a hamstring but a paperwork process nobody was responsible for. Set the case against the landscape of women's marathon running. Ethiopia and Kenya share almost the entire front of the major races, and both have enough depth to absorb individual losses. Aga is an important but replaceable node. Her six-year absence barely shifts the competitive balance of the event; it shifts her life, and it leaves a mark on the integrity record of the sport. What suffers more is the reputational premium of the Ethiopian distance-running brand — an intangible asset with real commercial value to race organisers, agents and sponsors. Stories like this do not collapse a sport with decades of depth, but they erode the trust that buyers and sellers rely on. One technical detail I expect to be raised repeatedly in the coming months: the possibility of retrospective review of stored samples. When a file includes a tampering finding, re-examining an athlete's long-term biological data is a logical step with precedent in comparable cases. The source does not address it, and I will not assert what has not been announced. But it is an open possibility, and it means this story may not end on 10 September. The popular reading of the case is a short sentence: the cover-up was worse than the crime. I agree with the conclusion, but the reading is lazy. It turns an infrastructure failure into a personal morality tale, and once everything is reduced to personal morality, nobody has to fix the process. The thing that needs fixing sits elsewhere: an elite athlete with nobody to ask whether this injection requires an exemption, and, once caught, nobody to ask where an honest declaration would have led. The great paradox of the file is that the softest category of substance produced the hardest sanction. Specified Substances exist so the system has room for mercy, for genuine medical error. A clumsy fabrication disabled that safety valve entirely. The athlete lost the right to be judged as someone who made a treatment mistake and was judged as someone who covered one up. The question worth asking is not whether the ban is heavy. It is that a case about paperwork teaches us more about the anti-doping system than every steroid case of the same year combined. The handling in parts of the media deserves comment too. They said girls don't understand tactics; I write so they have to read again — and this time, what needed reading was a prohibited list. Calling methylprednisolone an anabolic steroid is not merely a classification error; it flattens the story into a simple morality verdict, when the real story is more complicated: a common therapeutic drug, a real injury, a skipped procedure, and a group of people who chose to lie because they did not know how to tell the truth. The second risk in the telling is generalisation. Some coverage will infer that this reflects a systemic problem in Ethiopian athletics. The evidence in the file does not support that inference. A clinic that does not exist, a relative without registration, an old prescription pad — those are the signature of a clumsy individual case, not of an organised programme. At the same time, another layer deserves scrutiny: the adviser, the person who assembled the file, the person behind the decision to submit that sheet of paper. Tampering cases rarely stop at the athlete. I write about passes in order to write about choices in life, and this case is a sequence of choices. Choose the injection or choose the exemption. Choose disclosure or choose concealment. Choose to ask someone qualified or choose to ask someone in the family. Every choice carries a price, and the price of the last choice in that sequence turned out to be larger than all the earlier ones combined. There is one thing I do not know and will not pretend to know: whether the first injection really was for a knee injury. The source records only the athlete's explanation. Leaving one unresolved detail in place is how I remind myself that every file has a dark corner, and that an honest writer is one who lets that corner stay in the piece. What I am certain of is that the direction of the anti-doping fight has changed. It is no longer a fight of sample analysers; it is a fight of files, signatures, registration numbers and staff lists. In that fight, an athlete with no one beside them who understands the rules is walking a wire without a net. And when they fall, the system records the fall neatly, procedurally, and says very little about the fact that nobody ever handed them the net. Six years is a number produced by adding two clauses together, but it is lived as six seasons without a start line. Ruti Aga will not race a marathon at 33, 34, 35, 36 or 37. She will be somewhere off the roads while her contemporaries keep crowding each other at the 35th kilometre. And in the meantime, the question I take away from this file is not whether the ban is fair. It is this: who will teach a 20-year-old athlete that “I don't know, ask my doctor” is the safest sentence of their career — far safer than producing a piece of paper that three separate parties will disown within a week.